Point mutations in the α2 domain of HLA-A2.1 define a functionally relevant interaction with TAP  by Lewis, Jonathan W et al.
Point mutations in the a2 domain of HLA-A2.1 define a
functionally relevant interaction with TAP
Jonathan W. Lewis*, Anne Neisig†, Jacques Neefjes† and Tim Elliott*
Background: Glycoproteins encoded by the major histocompatibility complex
class I region (MHC class I) present peptide antigens to cytotoxic T cells (CTLs).
Peptides are delivered to the site of MHC class I assembly by the transporter
associated with antigen processing (TAP), and cell lines that lack this transporter
are unable to present endogenous antigens to CTLs. Although it has been
shown that a fraction of newly synthesized class I molecules are in physical
association with TAP, it is not known whether this interaction is functionally
relevant, or where on the class I molecule the TAP binding site might be.
Results: C1R cells transfected with a mutant HLA-A2.1 heavy chain (HC),
where threonine at position 134 in the a2 domain is changed to lysine (T134K),
are unable to present endogenous antigens to CTLs. We have studied the
biochemistry of this mutant in C1R cells, and found that a large pool of unstable
empty class I HC–b2m (b-2 microglobulin) heterodimers exist that are rapidly
transported to the cell surface. The T134K mutant seemed to bind peptide
antigens and assemble with b2m as efficiently as wild-type HLA-A2.1. However,
we show here that the inefficiency with which T134K presents intracellular
antigen is associated with its inability to interact with the TAP heterodimer.
Conclusions: These experiments establish that the class I–TAP interaction is
obligatory for the presentation of peptide epitopes delivered to the endoplasmic
reticulum (ER) by TAP. Wild-type HLA-A2.1 molecules in TAP-deficient cells are
retained in the ER, whereas T134K is rapidly released to the cell surface, but is
unstable, suggesting a role for the TAP complex as an intracellular checkpoint that
only affects the release of class I molecules with stably bound peptide ligands.
Background
Intracellular antigens are presented to cytotoxic T lymph-
ocytes (CTLs) by MHC class I molecules. Class I molec-
ules consist of heavy chain (HC), b-2 microglobulin (b2m),
and antigenic peptides, forming a trimolecular complex.
This is transported from the endoplasmic reticulum (ER) to
the cell surface where it can be recognized by the T-cell
receptor. Correct assembly of the class I–peptide complex
in the lumen of the ER is required for stable expression at
the plasma membrane. Peptide epitopes seem to come
predominantly from proteins degraded in the cytosol (see,
for example, [1,2]; reviewed in [3]). These peptides are
subsequently translocated across the ER membrane by the
heterodimeric transporter associated with antigen pro-
cessing (TAP; [4–6]). Longer peptides may be trimmed
subsequently in the ER to yield epitopes of an optimal size
for binding to class I molecules [7–9], and peptides that fail
to associate with class I molecules are removed from the ER
in an ATP-dependent way [7]. In vitro experiments have
shown that, as the binding of b2m and peptide to HC 
are co-operative, peptide binding and class I assembly 
are linked phenomena [10]. It is still unclear how the
trimolecular complex is assembled in vivo, but recent data
suggest that assembly of the peptide-receptive HC–b2m
heterodimer occurs in a complex with the ER-resident
chaperone protein calnexin [11,12], or the related protein
calreticulin (P. Cresswell, personal communication). In
addition, a physical association between HC–b2m het-
erodimers and the TAP complex has been observed [13,14],
and it has been suggested that this interaction is necessary
to promote the intracellular loading of peptides onto the
newly assembled class I molecules, although peptide
loading of class I molecules can also occur in TAP-deficient
cells if peptides are delivered directly to the ER in a signal
sequence-dependent way [8,15].
In the absence of TAP, HC and b2m assemble but form an
unstable complex as a direct result of their failure to bind
peptides [10]. Thus, mutants with defective or absent
TAP genes are unable to present epitopes derived from an
intracellular source unless they are delivered directly to
the ER in a signal-dependent way. Such mutants can,
however, present peptides when they are added exoge-
nously in the culture medium, as a proportion of these
unstable HC–b2m molecules reach the cell surface and are
peptide-receptive [16,17].
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Recently, several C1R transfectant cell lines have been
described that express the HLA-A2.1 HC with a variety of
single-site point mutations [18–20]. Some of these trans-
fectants, including T134K (where threonine at position
134 is changed to lysine), are unable to present antigen
following infection with virus (endogenous antigen), but
will effectively present synthetic peptide epitopes when
these are added to the culture medium (exogenous
antigen) [20]. Here we show not only that C1R-T134K
cells have an antigen-presentation phenotype similar to
the TAP-negative mutants, but also that, like wild-type
HLA-A2.1 expressed in TAP-negative mutants, T134K
fails to form stable intracellular complexes with endoge-
nous peptides even though C1R cells express a functional
TAP1–TAP2 heterodimer. We show this phenotype can
be explained by a defective interaction between T134K
and the TAP heterodimer.
Results
T134K expressed in C1R cells produces a .174-like
phenotype
It has previously been reported that C1R-T134K cells do
not present endogenously synthesized influenza A matrix
protein following viral infection, but will present exoge-
nously added peptide epitope [20]. We have shown that
the same is true of the HIV-pol(476–484) epitope follow-
ing infection of C1R-T134K cells with a recombinant vac-
cinia virus expressing HIV-pol (Table 1). Superficially,
this phenotype resembles that of wild-type HLA-A2.1
molecules when they are expressed in the TAP1–TAP2-
deficient cell lines .174 and T2 [21–23]. These lines syn-
thesize high levels of MHC class I HC and b2m, but
express low levels of the assembled class I HC–b2m het-
erodimers at the cell surface [21]. Intracellular class I mol-
ecules are unstable, but can be detected by
immunoprecipitation after they have been stabilized by
the addition of peptide [17] or b2m. Each of these obser-
vations can be explained by the fact that these mutants
lack the ability to supply newly synthesized class I mol-
ecules with peptides generated in the cytosol.
To test whether T134K expressed in the TAP1–TAP2-
competent cell line C1R displayed any of the other
characteristics shown by TAP1–TAP2-negative cell lines,
we first determined its cell-surface expression using a
fluorescence-activated cell sorter (FACS). In contrast to
an earlier report [20], where cell-surface expression of
T134K seemed to be normal, we found that C1R-T134K
cells expressed A2.1 at the cell surface at around 20 % of
wild-type levels, as detected by either BB7.2 or MA2.1 —
antibodies specific for determinants on the a1 and a2
domains of native A2.1 molecules (Table 2). Although
cell-surface levels are low, this does not reflect low levels
of HLA-A2.1 biosynthesis, as equivalent amounts of A2.1
could be immunoprecipitated from lysates of C1R-
T134K and C1R-A2.1 cells containing the stabilizing
peptide HIV-pol(476–484) (Fig. 1, compare lanes c and
e). Interestingly, in the absence of stabilizing peptide,
only around 20 % of wild-type levels of T134K could be
recovered from lysates by immunoprecipitation with the
conformation-sensitive antibody BB7.2 (Fig. 1, compare
lanes d and f). These results suggest that T134K
expressed in C1R cells behaves in a similar way to wild-
type molecules expressed in TAP1–TAP2-negative cell
lines (Fig. 1, lanes a and b).
T134K molecules are rapidly transported to the cell surface
as unstable complexes
Intracellular maturation of the mutant HLA-A2.1 molec-
ules in C1R cells was compared by pulse–chase analysis
with the maturation of wild-type molecules expressed in
both C1R and .174 cells. The rate at which A2.1 molecules
acquired resistance to endoglycosidase-H (endo-H) was
used as a measure of egress from the ER–cis-Golgi network
to the medial Golgi. At time points during the chase, dupli-
cate samples were taken and lysed in the presence or
absence of the stabilizing peptide HIV-pol(476–484).
Labelled HLA-A2.1 molecules were then immunoprecipi-
tated with the conformation-sensitive antibody BB7.2.
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Table 1
The presentation of HIV-pol(476–484) by C1R-T134K cells
following infection by recombinant vaccinia virus.
C1R-A2.1 C1R-T134K
10 nM peptide*
10:1† 52‡ 67
2:1 40 51
WR vacc
10:1 7 8
2:1 5 3
HIV-pol vacc
10:1 30 7
2:1 7 5
*HIV-pol(476–484) (ILKEPVHGV); †effector to target ratio; ‡percent
specific lysis.
Table 2
Cell-surface expression of wild-type and T134K HLA-A2.1 by
C1R transfectants.
Control antibody* BB7.2 MA2.1
C1R 15† 20 20
C1R-A2.1 9 898 940
C1R-T134K 12 214 205
.174 10 292 315
*B22.249, an IgG2a monoclonal antibody recognizing H2-Db; †mean
fluorescence intensity.
A2.1 molecules recovered from lysates lacking added
peptide represent those that assemble and mature as stable
heterodimers. The population of A2.1 molecules that
would normally fall apart during an overnight incubation in
the absence of peptide can be preserved by the addition of
stabilizing peptide. This technique allowed us to measure
the intracellular fate of both stable and unstable class I
molecules during a 1-hour chase.
Unlike an earlier report [20] indicating that the threonine-
to-lysine mutation in A2.1 does not affect its rate of intracel-
lular trafficking, we found that in C1R cells, T134K
acquires endo-H resistance with a half-time of 12 minutes,
which is considerably faster than wild-type A2.1, which
matures with a half-time of around 30 minutes (Fig. 2). In
C1R cells, around 50 % of wild-type A2.1 molecules seem
to be stabilized rapidly. In five separate experiments, this
proportion ranged from 50 to 70 %. This is consistent with
previous studies, which show that HC–b2m heterodimers
are stabilized within 2 minutes of their synthesis. The
remaining molecules are apparently degraded in an endo-
H-sensitive compartment. A stark contrast is observed with
T134K in C1R cells. In this case, although a small propor-
tion (around 25 %) of T134K molecules mature as stable
complexes, the majority enter the secretory pathway as
unstable heterodimers — they are recoverable only from
lysates to which the A2.1-binding peptide has been added.
These unstable molecules were released from the ER and,
having acquired endo-H resistance, disappeared over the
next 30 minutes (compare t = 32 min and t = 64 min in Fig.
2d). Thus, in C1R cells, all T134K molecules mature
rapidly, and the majority of these are detectable only as
unstable complexes which seem to be peptide-receptive.
The biogenesis of T134K molecules in C1R cells (Fig. 2)
has some similarities with the behaviour of wild-type A2.1
molecules in the TAP-negative cell line .174 in that, here
too, a significant proportion of A2.1 synthesized enters the
secretory pathway as unstable complexes. However,
unlike unstable T134K molecules, which are transported
much more rapidly, these acquire endo-H resistance with
a half-time comparable to wild-type A2.1 in C1R cells
(30 minutes). In longer pulse–chase experiments (data not
shown) these unstable endo-H-resistant wild-type molec-
ules were also seen to disappear over a period of around
30 minutes — presumably indicating their clearance from
the cell surface.
A small fraction of wild-type molecules in .174 cells and
T134K molecules in C1R cells do, however, assemble as
stable molecules, mature and can be detected at the cell
surface by FACS staining. As a result of work using the
TAP-negative cell line T2, it has been suggested that
these stable molecules represent wild-type A2.1 that
binds to peptides delivered to the ER in a TAP-indepen-
dent way [24,25]. To determine whether this was also the
case for T134K in C1R cells, we eluted the peptides from
T134K immunopurified from 1 × 1010 cells. The most
abundant peptide isolated in this way from T134K had
the sequence LLDVPTAAV, derived from the IP-30
signal sequence and which has been identified previously
as the most abundant peptide associated with wild-type
A2.1 molecules in a TAP-negative cell line [24,25]. No
peptides derived from cytosolic proteins were found asso-
ciated with T134K. In contrast, the most abundant
peptide eluted from wild-type A2.1 in control experi-
ments was derived from the cytosolic 60S ribosomal
protein. No signal-sequence-derived peptides were
found associated with wild-type A2.1 in these experi-
ments (J.W.L., unpublished observations). The main dif-
ferences between wild-type A2.1 in .174 and T134K in
C1R cells are therefore: the rate of trafficking of both
stable and unstable molecules; and the fact that the
majority of wild-type molecules in .174 never enter the
secretory pathway, whereas in T134K the majority leave
the ER and mature as unstable molecules.
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Figure 1
Most T134K molecules are unstable in C1R cells. Immunoprecipitation
of class I molecules with BB7.2 from metabolically labelled .174 (lanes a
and b), C1R-A2.1 (lanes c and d) and C1R-T134K cells (lanes e and f),
following addition of a saturating concentration (10 mM) of the A2.1-
stabilizing peptide ILKEPVHGV (lanes a, c and e) or PBS (lanes b, d
and f). Note that the ratio of intensity of heavy chain (HC) to b2m is the
same in C1R-A2.1 (lane c) and C1R-T134K (lane e) cells, indicating
that the stochiometry of HC–b2m complexes is the same for both wild-
type and mutant class I molecules.
HC
β2m
a b c d e f
The T134K heavy chain binds both peptide and b2m normally
One explanation for our observation that in TAP-compe-
tent cells most T134K assembles as unstable molecules is
that the mutation leads to an inherent inability to bind
peptide and b2m normally. First, we measured the ability
of three different A2.1-binding peptides to stabilize
‘empty’ wild-type A2.1 (expressed in .174 cells) and
T134K (expressed in C1R cells). This has been shown pre-
viously to be a reasonable estimate of the affinity of
peptide-binding at equilibrium [26]. Binding was dose-
dependent in all cases, and showed half-maximal effects at
comparable concentrations for both wild-type A2.1 and
T134K, as shown in Table 3. We also showed there was no
difference in the binding of peptides to immature (endo-
H-sensitive) versus mature (endo-H-resistant) class I mole-
cules, for wild-type or T134K (Table 3). This is important,
as it shows there is no destabilizing effect specific for the
T134K mutation of sialic-acid-containing complex sugars.
In addition, the rate of dissociation of one of the peptides
(radiolabelled ILKEPVHGV) was shown to be the same
for both wild-type and T134K, indicating that the threo-
nine-to-lysine mutation did not significantly alter the
binding kinetics of the A2.1 molecule, and that T134K was
able to form very stable complexes with peptide.
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Figure 2
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T134K molecules are transported rapidly to the cell surface as empty
receptors. The intracellular trafficking of wild-type (C1R-A2.1 and
.174) and mutant (C1R-T134K) A2.1 molecules. Pulse–chase analysis
of a cohort of A2.1 molecules was carried out and BB7.2-reactive
molecules were recovered from cell lysates after overnight preclearing
in the absence (a) or presence (b) of a saturating concentration
(15 mM) of stabilizing peptide. Only the heavy-chain bands are shown,
as human b2m is poorly visualized following a 10-minute pulse label.
(c) Quantitation of (a), representing the maturation of stably assembled
A2.1. (d) The fate of unstable A2.1 molecules, calculated from the
difference in band intensities between (a) and (b) (d = b–a). EHR:
endo-H resistant. EHS: endo-H sensitive. IOD: integrated optical
density in arbitrary units (see Materials and methods). All IODs were
normalized to the amount of immune complex recovered at the end of
the experiment. This was achieved by comparing the relative intensity
of the Coomassie blue-stained monoclonal antibody heavy-chain band
observed before autoradiography.
Second, we compared the intrinsic ability of wild-type
A2.1 and T134K heavy chains to assemble with human
b2m. As shown in Figure 3a,b, the assembly of class I
molecules in dilute lysates containing unstable HC–b2m
heterodimers can be driven by raising the concentration
of free b2m. Again, assembly is dose-dependent, and
seems to proceed according to the law of mass action.
The half-maximal concentration of b2m required for the
effect is around 0.5 mM for both wild-type A2.1 and
T134K (in both endo-H-sensitive and endo-H-resistant
forms), which indicates that the binding affinities of b2m
to these heavy-chains in the absence of peptide are the
same. This is also supported by the fact that we did not
observe any difference in the degree of reactivity with the
W6/32 antibody (which depends on b2m for recognition
of HLA molecules) when we used it to precipitate wild-
type and mutant molecules from digitonin lysates (see,
for example, Fig. 4).
The binding of peptides to HC–b2m increases the affinity
of HC for b2m by more than 10-fold [10]. The failure of
peptide and b2m to bind co-operatively in this way to
T134K could be another explanation for the observation
that most T134K seems to assemble as unstable complexes
with b2m. To assess the ability of peptide to stabilize
T134K–b2m heterodimers, we measured the rate of decay
of assembled T134K in the presence and absence of
peptide. We have previously shown that the loss of a confor-
mation-sensitive epitope on the a1/a2 domains of HC corr-
elates extremely well with the loss of b2m from the complex
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Table 3
The binding of three peptides to wild-type A2.1 and T134K.
Wild-type A2.1 T134K
Kd* (nM) Kd (nM) t½§ Kd (nM) Kd (nM) t½
mature† immature‡ (h) mature immature (9 h)
GILGFVFTL 3 5 ND 6 8 ND
ILKEPVHGV 8 5 220 10 8 260
TLWVDPYEV 50 50 ND 70 70 ND
*An estimation of the concentration of peptide required to effect half-
maximal stabilization of class I molecules in a cell lysate was taken as a
rough estimate of binding at equilibrium (Kd). †Mature molecules are
those which are endo-H insensitive. ‡Immature molecules are those
which are endo-H sensitive. §Half-time for dissociation.
Figure 3
T134K assembles normally with b2m in cell
lysates. The dose-dependent binding and
stabilization of wild-type (a) and T134K (b)
A2.1 with human b2m was measured for both
endo-H-sensitive (EHS) and endo-H-resistant
(EHR) class I molecules. The rate of
dissociation and subsequent loss of the
BB7.2 epitope was also measured for wild-
type (c) and T134K (d) A2.1 in absence of a
saturating concentration of stabilizing peptide.
Open symbols represent the number of
BB7.2-reactive complexes precipitable after
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[10]. We therefore measured the rate of decay of total
T134K–b2m heterodimers (this includes a mixture of both
mature and immature molecules) using this technique.
Figure 3c,d shows that the rate of decay of T134K has a
half-time of around 2.5 hours in the absence of peptide, and
more than 20 hours in the presence of peptide, and is con-
sistent with the equivalent rates of decay of wild-type A2.1
assembled in .174 cells. It seems, therefore, that the muta-
tion at position 134 does not alter the intrinsic ability of the
A2.1 molecule to assemble normally with b2m and peptides,
to give rise to a long-lived heterotrimeric complex in vitro.
To show that the same was true in vivo, we delivered a
‘pre-processed’ CTL epitope directly to the ER of C1R-
T134K cells. TAP-independent delivery of the influenza
A matrix protein (MP) epitope GILGFVFTL is opti-
mized by delivering it in the form of a minigene preceded
by an ER translocation signal sequence [25,27]. Table 4
shows that delivering the epitope in this way overcomes
the antigen-presentation defect seen with full-length MP
in both C1R-T134K and .174 cells. Influenza A MP is
clearly able to be processed and delivered to the ER of
C1R cells, as shown by the ability of wild-type A2.1 to
present this epitope in C1R cells infected with influenza
A/X31 (Table 4).
T134K does not associate with the TAP1–TAP2
heterodimer in C1R cells
Having established that the intrinsic properties of the
mutant A2.1 molecule are normal, we concluded that the
differences we observed between T134K and wild-type
A2.1 expressed in C1R cells must be due to the disrup-
tion of an intracellular process which acts on the newly
synthesized class I molecules, enabling them to assemble
stably with cytosolically derived peptides. We wondered,
therefore, whether the mutation at position 134 disrupted
an interaction between the class I molecule and the
TAP1–TAP2 heterodimer, leading to an inability to access
peptides that are delivered there by the transporter. This
might be expected to produce a block in the antigen-pre-
sentation pathway at the same stage as is seen in .174
cells, where TAP1–TAP2 is absent, resulting in the
assembly of unstable class I molecules. Figure 4 shows
that this is indeed the case. Whereas wild-type A2.1 and
HLA-Cw4 could be recovered in association with TAP, no
TAP-associated T134K could be detected. Note also that
T134K migrates higher than wild-type A2.1 in the IEF
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Table 4
Sensitization of C1R-A2.1 and C1R-T134K cells with L+G9L
vacc for lysis by CTLs.
C1R-A2.1 C1R-T134K .174
10 nM peptide*
10:1† 61‡ 70 78
2:1 52 57 60
WR vacc
10:1 10 10 6
2:1 7 3 1
Influenza A/X31
10:1 67 8 9
2:1 39 9 5
L+G9L vacc
10:1 28 24 38
2:1 17 13 22
*Influenza A matrix protein 55–63 (GILGFVFTL); †effector to target
ratio; ‡percent specific lysis.
Figure 4
T134K does not associate with the
TAP1–TAP2 heterodimer in C1R cells.
Metabolically labelled lysates of C1R-A2.1,
.174 and C1R-T134K cells were
immunoprecipitated with monoclonal antibody
W6/32 or anti-TAP2 antiserum. In addition,
monoclonal antibody BB7.2 was used to
immunoprecipitate wild-type A2.1 from C1R-
A2.1 and .174 cell lysates. The
immunoprecipitates were analysed by 1D-IEF
to resolve co-precipitating A2.1 and Cw4. The
data shown for C1R-A2.1 and .174 cells, and
C1R-T134K cells, were from separate
experiments. Note, W6/32 also precipitates
endogenous HLA-B51 (B51) expressed in
.174 cells.
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gel, which separates proteins according to their isoelectric
point (pI). This is due to the addition of positive charge by
the threonine-to-lysine mutation. HLA-Cw4 in association
with TAP is recovered equally well from lysates of C1R-
A2.1 and C1R-T134K cells. We do not know the origin of
the additional bands that co-precipitate with the anti-TAP
antiserum, nor whether they are specifically co-precipi-
tated. Only the band that equilibrates at a pI similar to
that of mono-sialylated T134K was reproducibly co-pre-
cipitated with anti-TAP (see, for example, Fig. 6). This
band is unlikely to be mono- or non-sialylated T134K
heavy chain because: it equilibrates at a different pI to
either of these; A2.1 in all its sialylated forms migrates as a
doublet, but this band is a singlet; the band persists after
the b2m band disappears, indicating that, unlike Cw4 in
the same cell, it is not associated with b2m, as might be
expected if it were T134K; and, sialylation occurs in the
trans-Golgi network whereas TAP localizes to the ER and
cis-Golgi network [28].
Association between TAP binding and trafficking rate of
class I complexes
The lack of TAP association could explain why the intra-
cellular loading of T134K is defective, but does not obvi-
ously account for why unstable (empty) molecules are
transported rapidly to the cell surface. One explanation
may be that TAP acts with a chaperonin-like function to
retain class I molecules in the ER until they are properly
folded. Indeed, Figure 5a shows that in C1R cells, the
release of wild-type molecules from TAP and their rate of
maturation (acquisition of sialic acids) are co-ordinated with
a half-time of around 30 minutes. Figure 5b also shows that
T134K does not associate with TAP at any time during its
rapid maturation. These data are consistent with observa-
tions made with other HLA class I alleles, where the rate of
intracellular trafficking correlates well with the amount of
that class I allele found bound to TAP in immunoprecipi-
tates ([29] and A.N., unpublished observations). To investi-
gate this relationship in more detail, we examined the
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Figure 5
TAP association and trafficking rate may be
linked phenomena. Pulse–chase analysis of a
cohort of A2.1 molecules was carried out, by
precipitating digitonin lysates of C1R-A2.1
(a), C1R-T134K (b) and C1R-S132C cells
(c) with either BB7.2 (left) or anti-TAP2
antiserum (right). HLA-A2.1 carrying no
(immature), one or two (mature) sialic acid
residues are labelled 0, 1 and 2
correspondingly. The autoradiographic
exposure we have chosen to show here,
although optimal for illustrating TAP co-
precipitation, is not optimized to demonstrate
the difference in trafficking between wild-type
A2.1 and S132C. This is shown better in (d),
where the trafficking rates of S132C and wild-
type A2.1 in C1R cells were measured using
the pulse–chase method described for Figure
2 . (e) Very few mature (endo-H resistant;
EHR) S132C molecules are peptide-
receptive, although immature (endo-H
sensitive; EHS) S132C molecules bind the
HIV-pol peptide in a dose-dependent way
similar to wild-type A2.1 and T134K
molecules.
5 6 7 8 9 10 11
0
4
8
12
16
EHR
EHS
Peptide (HIV-pol) conc. (1x10–x M)
IO
D
0
20
40
60
80
100
0 30 60 90 120
Time (min)
%
 E
nd
o-
H
 re
si
st
an
t C1R-A2.1
C1R-
S132C
0	 5	 10	 20	 30	 60	 120	 240 0	 5	 10	 20	 30	 60	 120	 240
(a)
(b)
(c)
(d) (e)
BB7.2
0	 5	 10	 20	 30	 60	 120	 240 0	 5	 10	 20	 30	 60	 120	 240
BB7.2
Anti-TAP2
Anti-TAP2
0	 5	 10	 20	 30	 60	120	240 0	 5	 10	 20	 30	 60	 120	 240
BB7.2 Anti-TAP2
C1R-A2
Cw4
β2m
0
1
2
C1R
T134K
Cw4
β2m
0
1
2
C1R
S132C
Cw4
β2m
0
1
2
Chase
time 
(min)
Chase
time 
(min)
Chase
time 
(min)
biogenesis of a second point mutant, in which serine at
position 132 is substituted for cysteine (S132C). This
mutant presents endogenous antigen efficiently, but
exogenous peptides very poorly [20]. S132C is transported
very slowly in C1R cells, having a half-time for maturation
of around 85 minutes (Fig. 5d). Significantly, it associates
with TAP for much of this time (Fig. 5c) and results in the
egress of stably assembled complexes. Figure 5e shows that
no S132C molecules leave the ER in a peptide-receptive
state, as the addition of peptides to endo-H-resistant mol-
ecules did not increase the number of complexes recovered
by BB7.2. There are sufficient numbers of immature
S132C molecules, however, to show that S132C binds
peptide normally in a lysate (half-maximal effect at around
1 × 10–8 M, compared to 0.5 × 10–8 M for wild-type A2.1 and
0.8 × 10–8 M for T134K, see Table 3). Thus, the biochem-
istry of S132C is consistent with its antigen-presentation
phenotype, and strongly supports the notion that the dura-
tion of TAP association is directly correlated with the
number or proportion of class I molecules that leave the ER
loaded with an optimal peptide. S132C and T134K may
therefore represent two ends of a spectrum along which all
class I molecules fall.
Discussion
Our results show that a single amino-acid substitution at
position 134 in the a2 domain of the HLA-A2.1. HC
(T134K) results in the intracellular assembly of unstable
complexes with b2m, which are transported to the cell
surface more than three times faster than the wild-type
A2.1 molecules expressed in the same cell. The mutant
molecules can bind to peptides and b2m normally in vitro.
However, no detectable association between the mutant
HC and the TAP1–TAP2 heterodimer was found in co-
immunoprecipitation experiments. The most likely expla-
nation to account for the observed behaviour of the
mutant molecules, therefore, is that they fail to become
loaded with high-affinity peptides in the lumen of the ER
as a consequence of this impaired association. This is the
first demonstration that the MHC class I–TAP interaction
is obligatory for the presentation of peptide epitopes
delivered to the ER by TAP. These results are consistent
with the functional phenotype of C1R-T134K cells, which
does not present endogenous antigen to CTLs, but pres-
ents exogenously added peptides normally. 
It remains to be seen whether the requirement for TAP
association that we observe for HLA-A2.1 can be extended
to other class I molecules. Although the behaviour of the
mutant heavy chains could be a consequence of studying
them in the cell line C1R (which has its origins in a g-irradi-
ated EBV-transformed B-cell line [30]), it is of interest to
note that Neisig et al. [29] have found other naturally occur-
ring HLA class I alleles that are capable of presenting
antigen, but that bind only poorly or undetectably to TAP.
The only difference among HLA alleles in the region
between residues 128 and 137 is an arginine/serine dimor-
phism at position 131. However, alleles with both arginine
and serine are represented among both efficient and ineffi-
cient TAP associators. Also, a recent report by Lee et al. [31]
showed that a soluble form of HLA-G loaded the same set
of endogenous peptides as its membrane-anchored counter-
part, despite a lack of demonstrable TAP association.
The behaviour of the T134K molecule in being unable to
form stable complexes with peptides in TAP-competent
cells is similar to that of another class I molecule, Ddm6 [32],
which has a non-conservative amino-acid substitution
within the same highly conserved region of the a2 domain
between residues 128 and 137 (the loop preceding, and
most of, the b4 strand). In all classical and non-classical
murine class I molecules, this sequence is EDLK-
TWTAAD (the human equivalent is EDLRSWTAAD). In
Ddm6, residue 133 is changed from tryptophan to arginine
(W133R), the only different residue between the Dd and
Ddm6 class I molecules. The level of cell-surface expression
of the mutant in normal cells is less than 10 % of the levels
of Kd or Dd expression in the same cells, and Ddm6 could
only be precipitated from pre-cleared lysates with antibod-
ies to the a3 domain, and not to the a1/a2 domains. Never-
theless, the mutant heavy chains were shown to acquire
mature N-linked oligosaccharides. Although experiments
were not carried out to test whether Ddm6 could be stabi-
lized with Dd-binding peptides, or whether it was able to
present Dd-restricted endogenous antigens, it is tempting to
speculate that the mutant molecules behave like T134K.
Taken together with our observations that a threonine-to-
lysine substitution at position 134 ablates the class I inter-
action with TAP, and that another mutation in this region
(S132C) results in slow trafficking and a phenotype consis-
tent with ‘hyper-efficient’ intracellular loading of pep-
tides, we suggest that residues in this region of the
molecule are responsible for dictating the efficiency of
loading by controlling the interaction of HC with TAP,
either directly or indirectly. Recent reports have also
implicated residues in both the a3 domain [33] and the
peptide-binding groove [29] in controlling the efficacy of
TAP binding. It remains to be seen whether these obser-
vations, along with our observation that solvent-exposed
residues in the a2 domain are also involved, will result in
an unified description of the class I–TAP interaction.
Various models can be proposed for the in vivo function of
TAP in the biogenesis of stable class I–peptide complexes
and their regulated release into the anteriograde transport
pathway. All of these must accommodate the observed
behaviour of T134K in CIR cells. The simplest is that the
conserved stretch between residues 128 and 137 forms all
or part of the interface between class I and TAP, and that
TAP has a chaperonin function, retaining class I het-
erodimers in the ER until a suitable peptide for binding is
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delivered (Fig. 6a). The T134K mutation may destabilize
this interface, resulting in the early entry of unloaded class
I molecules into the secretory pathway. This model,
however, would predict that wild-type A2.1 in a TAP-nega-
tive cell line should traffic rapidly, which it does not. Varia-
tions of this model therefore invoke an accessory molecule
which could bind to empty class I molecules and either
conduct them to TAP or be otherwise required for the for-
mation of an MHC class I–TAP complex (Fig. 6b). The
rate-limiting release of loaded class I molecules from the
HC–TAP complex might be controlled by TAP or by the
putative cofactor. Failure to associate with this factor would
bypass the rate-determining step and result in the prema-
ture release of unloaded, unstable molecules into the ante-
riograde transport pathway, as is the case for T134K. Poten-
tial candidates for such a factor include the ER chaperones
calnexin and calreticulin, as well as the component that is
presumed to be missing in the recently described mutant
cell line .220 [34]. In .220 cells, two transfected HLA class I
alleles display defective assembly as a result of their
impaired interaction with TAP [35]. This model accommo-
dates the observation that in the TAP-negative cell line
.174 (which might be expected to express the accessory
molecule), wild-type A2.1 is transported slowly, and pre-
dicts that the rapid transport of T134K might be TAP-inde-
pendent and independent of peptide binding in the ER.
To test this, we are currently investigating whether the rate
of transport for T134K and S132C is TAP-dependent.
Materials and methods
Cells and antibodies
The human B-lymphoblastoid cell line C1R, a derivative of Hym2 [36],
was transfected with plasmids encoding the genes for wild-type A2.1,
A2.1 with a single coding change resulting in a threonine to lysine substi-
tution at position 134 (T134K), and a similar point mutation resulting in a
serine to cysteine substitution at position 132 (S132C), by M. Matsui
(Duke University; [20]) and were a kind gift from J. Frelinger. Cell lines
were cultured in RPMI 1640 cell culture medium (Gibco Laboratories)
supplemented with 10 % FCS, 2 mM L-glutamine, and penicillin/strepto-
mycin (Gibco BRL) at 37 °C; 5 % CO2. The C1R cell line, which has one
copy of chromosome 6, does not express endogenous HLA-A or HLA-B
but does express endogenous Cw4 [30]. The transporter-deficient cell
line LBL 721.174 (.174) was kindly provided by R. DeMars. An HLA-
A2.1-restricted CTL line recognizing the influenza A matrix protein
epitope GILGFVFTL was a gift from V. Braud (University of Oxford), and
the A2.1-restricted anti-HIV-pol epitope ILKEPVHGV was a gift from A.
McMichael (University of Oxford).
Rabbit anti-TAP2 serum was made by constructing a GST fusion protein
containing the ATP-binding domain of TAP2 (amino acids 507–798).
Templates for PCR were a generous gift from J. Trowsdale (ICRF,
London) and the fragments were cloned in the pGEX vector. The GST-
fusion proteins were over-expressed in E. coli, isolated as inclusion
bodies by differential centrifugation and injected into rabbits. The mono-
clonal antibodies used were anti-HLA-A2.1 (BB7.2 [37]) and anti-HLA-A,
HLA-B, HLA-C (W6/32 [38]).
Peptide synthesis
All peptides were synthesized by solid-phase syntheses using fmoc
chemistry, cleaved with TFA and purified to more than 95 % homogeneity
by reversed-phase HPLC. Peptides used in this investigation were:
GILGFVFTL (influenza A matrix protein residues 55–63, [39]);
ILKEPVHGV (HIV-pol residues 476–484, [40]) and TLWVDPYEV
(unidentified self peptide eluted from HLA-A2.1 [41]).
Cell-surface expression of MHC class I detected by flow
cytometry
Cells (1 × 106) were washed into PBS containing 0.1 % BSA before
adding a saturating concentration of monoclonal antibody. After 30 min at
4 °C, cells were washed three times in PBS/BSA, then resuspended in a
saturating concentration of fluorescein-conjugated goat anti-mouse IgG
(Sigma, St Louis). The cells were incubated for 30 min at 4 °C, washed
three times, resuspended in PBS and analysed by FACS. Each sample
analysed comprized a minimum of 5 × 104 viable cells.
Metabolic labelling, pulse–chase, and immunoprecipitations of
class I molecules
Cells (1 × 107 per experimental point) were washed in PBS and starved for
40 min in 5 ml methionine/cysteine-free RPMI 1640 media, containing
10 % dialysed FCS. After labelling cells for 10 min with 100mCi [35S]
methionine/cysteine trans-label (Amersham) per 107 cells at 37 °C, they
were chased for 0, 8, 16, 32, 64 min in RPMI 1640 medium supplemented
with 200 mM methionine/cysteine and 10 % FCS. At each time point, cell
aliquots were removed, washed in ice-cold PBS and lysed in 1 ml ice-cold
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Figure 6
Models to account for the intracellular role 
of TAP in regulating the assembly of stable
class I–peptide trimeric complexes. (a) Newly
assembled HC–b2m complexes associate
with TAP, where they acquire stabilizing
ligands and are subsequently released.
Release of stabilized HC–b2m–peptide
complexes is the rate-determining step here.
(b) Alternatively, newly assembled complexes
could bind to a molecule which either
chaperones them to TAP or acts as a cofactor
for TAP binding and which rescues empty
molecules from the anteriograde transport
pathway until they acquire stably bound
peptide ligands, whereupon they are released.
A: step blocked by T134K mutation. B: rate-
limiting step.
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Tris lysis buffer (pH 7.4), containing 0.5 % NP-40 and 0.5 % Mega-9, 5 mM
iodoacetamide and 2 mM PMSF (Sigma). For aliquots lysed in the pres-
ence of stabilizing peptide, 15 mM HIV-pol(476–484) was added to the
lysis mix. After 15 min at 4 °C, the nuclei were removed by centrifugation
and the supernatants were precleared overnight at 4 °C with 20ml of fixed
Staphylococcus aureus (Sigma) made up in lysis buffer.
Assembled class I molecules were immunoprecipitated with BB7.2
(10 mg ml–1 for 1 h) and 5 % (w/w) protein A–Sepharose beads (Sigma).
After washing the immunoprecipitates three times in lysis buffer, they
were subjected to endoglycosidase-H digestion overnight before being
analysed on a 10 % SDS–PAGE gel under reducing conditions. Gels
were fixed, stained, treated with Amplify (Amersham), dried and visualized
by autoradiography at –80 °C. Quantitation of autoradiograms was
achieved by scanning using a MilliGen Bioimage Analyser which
expresses band intensities as an integrated optical density (IOD).
Endoglycosidase-H treatment
Endoglycosidase-H (Boehringer Mannheim) digestion of immunoprecipi-
tates was performed by resuspending the samples in 30 ml of 50 mM
sodium citrate buffer (pH 5.5), containing 0.2 % SDS, heating to 95 °C
for 5 min, and digesting with 3 U of endoglycosidase-H overnight at
37 °C.
Peptide or b2m binding in vitro
Increasing concentrations of b2m or stabilizing peptide were added to
cell lysates to determine binding affinities for mutant and wild-type class
I molecules. Cells were labelled for 15 min with [35S] methionine/
cysteine as described above. To enable the determination of binding
affinities for both endoglycosidase-H-resistant (EHR) and endo-
glycosidase-H-sensitive (EHS) forms, each cell line was chased with
cold RPMI 1640 medium supplemented with 200 mM methionine/cys-
teine and 10 % FCS (as above) until equal amounts of both EHR and
EHS class I molecules were obtained. (For pulse–chase experiments
above, C1R and .174 cells were chased for 30 min, C1R-T134K cells
were chased for 12 min, and C1R-S132C cells were chased for
60 min.) After washing cells in cold PBS, samples were lysed in ice-cold
Tris lysis buffer (as above) in the presence of a decreasing concentration
of either b2m or peptide. Samples were then precleared for 1 h with
Staph A and immunoprecipitated using BB7.2, washed three times,
exposed to endoglycosidase-H overnight and analysed as above by
12 % SDS–PAGE.
b2m dissociation assay
The stability of wild-type A2 and T134K class I complexes was deter-
mined in vitro by measuring the rate of decay of the BB7.2 epitope result-
ing from the dissociation of b2m from HC. A2.1 molecules in .174 and
C1R-T134K cells were labelled with [35S] methionine/cysteine and
chased as described previously to obtain equal amounts of EHS and
EHR class I molecules. Cells were then lysed in Tris lysis buffer contain-
ing 0.5 % NP-40, aliquotted and kept on ice. At intervals following lysis
(0, 1, 2, 3, 8 and 20 h), stabilizing HIV-pol peptide and BB7.2 antibody
were added together to the lysate and immunoprecipitated after 1 h (as
above). For one sample, peptide was added at the time of lysis (0 h) and
BB7.2 was added at 20 h. Samples were analysed on SDS–PAGE after
endoglycosidase-H treatment (as above).
Association of class I molecules with TAP
We starved 2 × 107 cells of each cell line for 40 min in 1 ml
methionine/cysteine-free RPMI 1640 medium supplemented with 10 %
FCS. The cells were pelletted and resuspended in 500 ml fresh methion-
ine/cysteine-free RPMI 1640 + 10 % FCS and labelled with 250 mCi
35S-methionine/cysteine for 10 min at 37 °C. Cells were washed twice
with cold PBS and lysed in 500 ml 1 % digitonin-containing lysis buffer
(1 % (w/v) digitonin (Sigma), 50 mM Tris–HCl (pH 7.5), 5 mM MgCl2 and
150 mM NaCl) for 30 min on ice. Each lysate was split into equal por-
tions, pre-cleared overnight with normal rabbit serum (NRS) and immuno-
precipitated with either BB7.2, W6/32 or anti-TAP2 antibodies. The
immunoprecipitations were recovered with protein A–Sepharose beads
(Sigma) for 1 h and the beads were washed three times in lysis buffer
containing 0.5 % digitonin before analysis by 1D-IEF.
Pulse–chase analysis to follow assembly of class I molecules
and TAP–class I interactions
We starved 1 × 108 cells for 40 min in 2 ml methionine/cysteine-free
RPMI 1640 medium with 10 % FCS. Cells were pelletted, resuspended
in 500 ml fresh RPMI 1640 medium supplemented with 10 % FCS and
labelled with 500 mCi 35S-methionine/cysteine for 10 min at 37 °C. Cells
were chased for 0, 5, 10, 20, 30, 60, 120, 240 and 480 min in RPMI
1640 medium supplemented with 1 mM methionine/cysteine and 10 %
FCS. Cells were washed in ice-cold PBS before lysis in 1 % digitonin-
containing lysis buffer for 1 h on ice. Each lysate was divided into two
portions, pre-cleared with NRS and immunoprecipitated with either
BB7.2 or anti-TAP2 antibodies. All samples were analysed by 1D-IEF.
One-dimensional isoelectric focusing (1D-IEF)
1D-IEF was performed as described [42].
Dissociation rate of peptide from class I
The peptide ILKEVPHGV was radio-iodinated to a specific activity of
1.3 × 1016 cpm mol–1 using the chloramine T method. C1R, .174 and
C1R-T134K cells (1 × 108) were lysed in 1 ml cold lysis buffer and nuclei
were removed by centrifugation. Peptide (5 × 107 cpm) was then added
to each sample along with human b2m and diluted to a final concentration
of 2 × 107 cell equivalents per ml and 3 mg ml–1 b2m. This mixture was
allowed to equilibrate overnight at 4 °C. The next day the equilibrium
mixture was diluted 1:1 with a 0.2 mM solution of unlabelled ILKEPVHGV
in cold lysis buffer, thus effecting a 100-fold molar excess of cold over
hot. At various times during the following 300 h, 2 × 107 cell equivalents
were removed and precipitated with BB7.2, as described above. The
immunoprecipitates were washed four times and the resulting isolates
were quantitated with a Rackgamma g-counter (LKB). Background
binding was determined by allowing 2 × 107 cell equivalents of lysate to
equilibrate with 5 × 106 cpm hot ILKEPVHGV in a solution of 0.1 mM cold
peptide. Specific peptide-binding to wild-type A2.1 and T134K were cal-
culated by subtracting background cpm obtained in the sham binding
control with a lysate of untransfected C1R cells.
Construction of recombinant vaccinia virus and CTL assays
Recombinant vaccinia virus expressing a minigene encoding the optimal
influenza A matrix protein epitope GILGFVFTL preceded by the haemag-
glutinin ER translocation signal sequence MKANLLVLLCALAAADA
(L+G9L-vacc) was constructed as described in [8]. Briefly, the synthetic
minigene was cloned into the plasmid pSC11.302.R.L+ as an
NcoI–BamHI fragment. The resulting construct was then introduced into
the thymidine kinase locus of WR vaccinia by homologous recombination
using standard techniques.
The ability of recombinant vaccinias to sensitize C1R-A2.1 and C1R-
T134K cells was assessed by infecting 1 × 106 of each for 1 h during
51Cr-labelling at a multiplicity of infection of 20. Influenza A/X31 infec-
tions were with 200 ml allantoic fluid. The media with virus and 51Cr were
then washed away and the cells were incubated for an additional 2 h at
37 °C. Following two further washes in R10, the target cells were
assayed for their susceptibility to lysis by CTLs in a 4-hour chromium-
release assay. Where peptide sensitization was assayed, targets were
pulsed with 10 nM peptide 1 h prior to the start of the CTL assay.
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